Gopal Krishna - Seelos Therapeutics Head Operations
| SEEL Stock | USD 0.39 0.11 22.00% |
Insider
Gopal Krishna is Head Operations of Seelos Therapeutics
| Phone | 646 293 2100 |
| Web | https://seelostherapeutics.com |
Seelos Therapeutics Management Efficiency
The company has return on total asset (ROA) of (2.6111) % which means that it has lost $2.6111 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.842) %, meaning that it created substantial loss on money invested by shareholders. Seelos Therapeutics' management efficiency ratios could be used to measure how well Seelos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Seelos Therapeutics currently holds 14.23 M in liabilities with Debt to Equity (D/E) ratio of 0.73, which is about average as compared to similar companies. Seelos Therapeutics has a current ratio of 3.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Seelos Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Seelos Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Seelos Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Seelos to invest in growth at high rates of return. When we think about Seelos Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA CMA | Pulmatrix | 69 | |
| MD MA | Mind Medicine | 44 | |
| Annie Mack | Akari Therapeutics PLC | N/A | |
| Rolando MD | ATAI Life Sciences | 63 | |
| Aaron Bartlone | Cybin Inc | 57 | |
| Florian Brand | ATAI Life Sciences | 37 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| , MBA | Soleno Therapeutics | N/A | |
| Magnus Halle | GH Research PLC | 27 | |
| Melissa BradfordKlug | Akari Therapeutics PLC | 54 | |
| John Kanakis | Cybin Inc | 43 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Joanne MD | Iteos Therapeutics | 52 | |
| RAC Sakai | Tempest Therapeutics | N/A | |
| Matthew Gall | Iteos Therapeutics | 47 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Yvonne McGrath | Iteos Therapeutics | 50 | |
| Schond Greenway | Mind Medicine | 52 | |
| MD MBA | Mind Medicine | N/A | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Ryan Baker | Iteos Therapeutics | N/A | |
Management Performance
| Return On Equity | -5.84 | |||
| Return On Asset | -2.61 |
Seelos Therapeutics Leadership Team
Elected by the shareholders, the Seelos Therapeutics' board of directors comprises two types of representatives: Seelos Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seelos. The board's role is to monitor Seelos Therapeutics' management team and ensure that shareholders' interests are well served. Seelos Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seelos Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gopal Krishna, Head Operations | ||
| Michael Golembiewski, Chief Officer | ||
| Kimberly Farrand, Senior Operations | ||
| Raj JD, Chairman, Founder | ||
| Anthony Marciano, Chief Officer | ||
| Karen Fusaro, Senior Operations | ||
| Tim MD, Chief Officer |
Seelos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Seelos Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.84 | |||
| Return On Asset | -2.61 | |||
| Profit Margin | 2.03 % | |||
| Operating Margin | (8.35) % | |||
| Current Valuation | 10.45 M | |||
| Shares Outstanding | 581 K | |||
| Shares Owned By Insiders | 0.49 % | |||
| Shares Owned By Institutions | 4.46 % | |||
| Number Of Shares Shorted | 170.89 K | |||
| Price To Book | 15.10 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Seelos OTC Stock
Seelos Therapeutics financial ratios help investors to determine whether Seelos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Seelos with respect to the benefits of owning Seelos Therapeutics security.